Gilead’s Quad Makes It Through FDA Panel Review Despite Renal Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiviral Drugs Advisory Committee votes 13-1 in favor of the four-drug-in-one HIV treatment. Panel members offer a host of suggestions for post-marketing studies, including determining the best means for detecting Quad-related renal injury early.